# Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant

> **NCT03755310** · PHASE2 · UNKNOWN · sponsor: **Diego García-Borreguero, MD, PhD** · enrollment: 43 (estimated)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Suvorexant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03755310
- **Lead sponsor:** Diego García-Borreguero, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2018-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755310, "Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03755310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*